真实世界队列中肿瘤小分子激酶抑制剂的治疗药物监测:年龄是否重要?
该真实世界研究分析了454例接受7种小分子激酶抑制剂治疗患者的616份血浆样本,比较≥70岁与<70岁患者的谷浓度。多数激酶抑制剂暴露在两组间无显著差异,但老年患者达拉非尼谷浓度显著更高(62 vs 53 ng ml-1,P=0.02)。有预设靶浓度的药物中,68%老年和61%年轻患者达到目标。
要点
- 多数小分子激酶抑制剂暴露在老年与年轻患者间无显著差异
- 老年患者达拉非尼谷浓度显著高于年轻患者(P=0.02)
- 有预设靶浓度药物中68%老年和61%年轻患者达到目标
核心结论
- 多数纳入的小分子激酶抑制剂在老年与年轻患者中暴露相当,仅达拉非尼在老年患者中暴露更高。
- 达拉非尼缺乏绝对靶浓度,其老年患者暴露升高的临床相关性尚不明确。
- 对于其他纳入的激酶抑制剂,数据提示高龄对暴露无临床相关影响。
研究设计与样本
- 真实世界队列研究,纳入454例常规治疗患者,中位年龄61岁(范围20-93岁)。
- 使用经验证的检测方法测定616份样本的激酶抑制剂血浆浓度,计算谷浓度并在两个年龄组(≥70岁与<70岁)间比较。
- 对具有临床意义靶浓度的激酶抑制剂(厄洛替尼、伊马替尼、帕唑帕尼、舒尼替尼和维莫非尼),评估高龄对达标情况的影响。
主要发现
- 老年患者达拉非尼谷浓度显著高于年轻患者(P=0.02;62 ng ml-1(CV 41%)vs. 53 ng ml-1(CV 46%))。
- 高龄对厄洛替尼、伊马替尼、帕唑帕尼、舒尼替尼、曲美替尼和维莫非尼的暴露无显著影响。
- 对于有预设靶浓度的激酶抑制剂,68%的老年患者和61%的年轻患者达到目标浓度。
关键数值与推荐
- 达拉非尼谷浓度:老年患者62 ng ml-1(CV 41%),年轻患者53 ng ml-1(CV 46%),P=0.02。
- 有预设靶浓度的激酶抑制剂达标率:老年患者68%,年轻患者61%。
临床怎么用
- 对于多数小分子激酶抑制剂,高龄本身不提示需要常规调整剂量或加强治疗药物监测。
- 使用达拉非尼的老年患者可考虑关注暴露升高情况,但因缺乏绝对靶浓度,临床意义需结合个体评估。
局限性
- 达拉非尼缺乏绝对靶浓度,其暴露升高的临床相关性不明确。
- 真实世界研究设计可能存在混杂因素,样本来自常规治疗患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Pharmacokinetics of small molecule kinase inhibitors (KIs) used in cancer treatment may alter with increasing age, but results are conflicting. This study aims to compare exposure to KIs between older and younger patients (≥70 and <70 years) in clinical practice. METHODS: KI plasma concentrations of routinely treated patients were measured using validated assays. Calculated trough concentrations were compared in both age groups. For KIs with a clinically meaningful target concentration (erlotinib, imatinib, pazopanib, sunitinib and vemurafenib), influence of older age on target attainment was assessed. RESULTS: We analysed 616 samples from 454 patients (median age: 61; range 20-93 years), treated with dabrafenib (n = 105), erlotinib (n = 49), imatinib (n = 165), pazopanib (n = 63), sunitinib (n = 87), trametinib (n = 95) and vemurafenib (n = 52). Older age did not significantly influence exposure to erlotinib, imatinib, pazopanib, sunitinib, trametinib and vemurafenib. Elderly patients had significantly higher dabrafenib trough concentrations than younger patients (P = 0.02; 62 ng ml-1 (coefficient of variation [CV] 41%), vs. 53 ng ml-1 (CV 46%), respectively). For KIs with a predefined target concentration, 68% of older and 61% of younger patients reached target. CONCLUSIONS: In this real-world study, exposure to most included KIs was comparable in older and younger patients, except for dabrafenib, which showed higher exposure in older patients. In the absence of an absolute target for this KI, clinical relevance remains unclear. For all other included KIs, our data suggest no clinically relevant influence of older age on KI exposure.
引用
- Crombag MBS, van Doremalen JGC, Janssen JM, et al. Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter? Br J Clin Pharmacol. 2018. PMID: 30068020. doi:10.1111/bcp.13725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。